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Abstract
Introduction: Osteoporosis can be a complication of ankylosing spondylitis (AS), but diagnosing spinal
osteoporosis can be difficult since pathologic new bone formation interferes with the assessment of the bone
mineral density (BMD). The aims of the current study were to investigate prevalence and risk factors for reduced
BMD in a Swedish cohort of AS patients, and to examine how progressive ankylosis influences BMD with the use
of dual-energy x-ray absorptiometry (DXA) of the lumbar spine in different projections.
Methods: Methods of assessment were questionnaires, back mobility tests, blood samples, lateral spine
radiographs for syndesmophyte grading (mSASSS), DXA of the hip, radius and lumbar spine in anteroposterior (AP)
and lateral projections with estimation of volumetric BMD (vBMD).
Results: AS patients (modified New York criteria), 87 women and 117 men, mean age 50 ± 13 years and disease
duration 15 ± 11 years were included. According to World Health Organization (WHO) criteria 21% osteoporosis
and 44% osteopenia was diagnosed in patients > = 50 years. Under age 50 BMD below expected range for age
was found in 5%. Interestingly lateral lumbar DXA showed significantly lower BMD and revealed significantly more
cases with osteoporosis as compared with AP DXA. Lumbar vBMD was not different between sexes, but women
had significantly more lumbar osteoporosis measured with AP DXA (P < 0.001). Men had significantly higher
mSASSS (P < 0.001). Low BMD was associated with high age, disease duration, mSASSS, Bath Ankylosing
Spondylitis Metrology Index (BASMI), inflammatory parameters and low body mass index (BMI). Increasing mSASSS
correlated significantly with decreasing lateral and volumetric lumbar BMD, while AP lumbar BMD showed
tendency to increase.
Conclusions: Osteoporosis and osteopenia is common in AS and associated with high disease burden. Lateral and
volumetric lumbar DXA are more sensitive than AP DXA in detecting osteoporosis and are less affected by
syndesmophyte formation.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease, mainly affecting the sacroiliacal
joints, vertebrae and intervertebral discs, leading to syn-
desmophyte formation and impaired back mobility. In
AS two enhanced but opposite bone remodelling pro-
cesses are taking place in close vicinity within the spine;
these are pathologic new bone formation in the cortical
zone of the vertebrae, the zygapophyseal joints, and the
ligamentous apparatus and excessive loss of trabecular
bone in the centre of the vertebral body leading to
osteoporosis. Earlier studies have demonstrated an
increased prevalence of osteoporosis and significantly
lower bone mineral density (BMD) in AS patients com-
pared with sex and age matched controls [1,2]. Osteo-
porosis has also been shown to be present in mild AS
and in early disease [2,3]. AS patients have a high risk
* Correspondence: Eva.Klingberg@vgregion.se
1Department of Rheumatology and Inflammation Research, Sahlgrenska
Academy at University of Gothenburg, Guldhedsgatan 10A, S-413 46
Göteborg, Sweden
Full list of author information is available at the end of the article
Klingberg et al. Arthritis Research & Therapy 2012, 14:R108
http://arthritis-research.com/content/14/3/R108
© 2012 Klingberg et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
of vertebral fractures, which can be complicated by neu-
rological injuries [4,5].
In advanced AS it can be difficult to interpret lumbar
spine BMD measured with dual-energy x-ray absorptio-
metry (DXA) in the anteroposterior (AP) projection.
The new bone formation that is characteristic of AS
causes an overestimation of the total BMD and values
can be normal or high, even when osteoporosis is pre-
sent. Spinal hyperostosis in AS is frequently located
around the zygapophyseal joints, the vertebral endplates
and the annulus fibrosus of the discs, and to a lesser
extent, on the lateral sides [6]. Lateral DXA scanning of
the lumbar spine allows exclusive examination of the
vertebral body, which consists of 80% trabecular bone,
and excludes the zygapophyseal joints, endplates and
both anterior and posterior syndesmophytes from the
measurement. Consequently, lateral scanning could be a
way to reduce the problem of overestimation of lumbar
spine BMD in AS. With older single-beam DXA systems
patients were examined lying on their side and the pre-
cision was low. Modern lateral scans with the patient
positioned supine offer precision similar to regular AP
spine DXA scans [7].
The combination of AP and lateral DXA allows assess-
ment of three-dimensional volumetric BMD (vBMD =
bone mineral content/volume). Areal BMD (aBMD) is
measured two-dimensionally, without taking the size of
bone in the third dimension into account. Consequently,
aBMD depends on both bone density and bone size,
whereas vBMD is independent of bone size. Men have lar-
ger bones than women and consequently have higher
aBMD, but vBMD is equal in both sexes [8,9].
BMD varies between different populations. Sweden has
a high prevalence of osteoporosis and osteoporosis-
related fractures [10-12]. Although studies of osteoporo-
sis in AS have been performed in other countries, this is
to our knowledge the first study in Scandinavia. The aims
of the present study were to investigate the prevalence of,
and risk factors for osteoporosis in patients with AS, to
compare lumbar spine BMD measured in the AP and lat-
eral projection, including estimated vBMD, and to study
how these measures change with progressive ankylosis.
Materials and methods
Patients
The patients were recruited from three participating
centres in western Sweden; the Rheumatology Clinic at
Sahlgrenska University Hospital in Gothenburg and the
Rheumatology Clinics at the Borås and Alingsås county
hospitals. The inclusion criterion was AS according to
the modified New York criteria [13]. Exclusion criteria
were psoriasis, inflammatory bowel disease, dementia,
pregnancy and difficulties in understanding Swedish. All
patients meeting the study criteria were invited to
participate. Informed consent was obtained according to
the Declaration of Helsinki. The study was approved by
the regional ethics committee in Gothenburg.
Physical examination and questionnaires
Physical examinations, including the Bath Ankylosing
Spondylitis Metrology Index (BASMI), were all per-
formed by the same physician (EK). The patients
answered questionnaires concerning risk factors for
osteoporosis, medical history, medication and the Bath
Ankylosing Spondylitis Disease Activity Index (BAS-
DAI), Bath Ankylosing Spondylitis Functional Index
(BASFI) and Bath Ankylosing Spondylitis Patient Global
score (BAS-G) [14-17]. The Ankylosing Spondylitis Dis-
ease Activity Score (ASDAS) was calculated using a pre-
viously described formula [18,19].
Physical activity was divided into three levels of inten-
sity (light, moderate and heavy) and reported in hours
per week for leisure time, at home and at work, using
two validated questionnaires; the Leisure Time Physical
Activity Instrument (LTPAI) and Physical Activity at
Home and Work Instrument (PAHWI) [20]. Lifetime
use of glucocorticoids, converted into milligrams of pre-
dnisone, was estimated by examining the medical
records and questioning patients about previous gluco-
corticoid injections and oral prednisone use. Fracture
risk assessment (FRAX) for the % ten-year probability of
major osteoporotic and vertebral fractures respectively,
was calculated using the FRAX tool developed from a
Swedish cohort. The FRAX tool applies only to patients
40 years or older. The probability of fracture is calcu-
lated using known risk factors for fractures, and BMD
of the femoral neck [21].
Bone mineral density
BMD of the lumbar spine in the AP (vertebrae L1 to L4)
and lateral (L2 to L4) projections, the left hip (femoral
neck and total hip regions) and the non-dominant fore-
arm (radius) was measured using a DXA scanner (Holo-
gic Discovery A, Hologic Inc, Bedford, MA, USA). The
coefficients of variation for repeat scan precision were
0.39% for the AP and 0.60% for the lateral lumbar DXA
measurements. For patients aged 50 years or older the
following World Health Organization (WHO) defini-
tions of osteopenia and osteoporosis were used: osteope-
nia, T-score < -1 to > -2.5 SD (compared to the young
normal mean), and osteoporosis, T-score ≤ -2.5 SD. The
lowest value of BMD measured in the lumbar spine,
total hip or femoral neck was used [22]. For patients
under the age of 50 a Z-score ≤ -2.0 SD (compared to
the age-matched mean) was considered to be below the
expected range for age [23]. For calculation of T- and
Z-scores the BMD values of the patients were compared
with reference values provided by the DXA scanner
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analysis software. T- and Z-scores were not available for
lateral lumbar spine DXA measured in men or for lum-
bar spine vBMD measured in men or women.
Radiography
Lateral radiographs of the cervical, thoracic and lumbar
spine were acquired and changes related to AS were
assessed using the modified Stoke Ankylosing Spondylitis
Spine Score (mSASSS). The score includes the anterior
corners of vertebrae C2 to T1 and T12 to S1, which are
graded with 0 to 3 points each (0 = normal, 1 = erosion,
sclerosis or squaring, 2 = syndesmophyte, 3 = bridging
syndesmophyte). The remaining thoracic spine is not
included in the score. The scoring scale ranges from 0 to
72 [24].
Laboratory tests
Blood samples were analysed by standard laboratory
techniques at the participating hospitals. The mean level
of erythrocyte sedimentation rate (ESR) during the last
five years was calculated using the first recorded ESR
test for each year. When the patient had an infection
the concomitant ESR test was excluded and replaced by
the subsequent test.
Statistics
Statistical analyses were performed using PASW Statis-
tics 18.0 (SPSS Inc., IBM, Chicago USA). Descriptive sta-
tistics are presented as median and range and/or mean
and standard deviation (SD). The t-test was used for
comparison of normally distributed demographic and
disease-related variables and the Mann-Whitney U-test
was used to analyse variables that were not normally dis-
tributed. The chi-square test was used to compare cate-
gorical variables. Correlations were calculated using
Spearman’s correlation (rs). For dichotomous variables,
yes was coded 1 and no was coded 0. All tests were two-
tailed and P < 0.05 was considered statistically significant.
Linear regression was run with BMD at different mea-
surement sites as the outcome and logistic regression
was run with the categorical variable low BMD T-score
(yes/no) as the outcome. Covariates in both calculations
were the variables that were significantly correlated with
BMD in the first analyses.
Results
Of the 538 AS patients registered in the hospitals’ data-
bases, 177 patients did not meet the modified New York
criteria for AS or had exclusion criteria. Out of a total
of 361 patients invited to participate, 72 declined, 60 did
not respond to the invitation and 19 did not meet the
inclusion criteria. Of the 210 patients included, 6 did
not attend the DXA or radiography appointments and
were therefore excluded. The patients who fulfilled the
inclusion criteria but declined to participate or did not
respond to the invitation (n = 151) were significantly
younger than the patients included in the study (46 ±
13 years vs. 50 ± 13 years; P = 0.007), but the sex distri-
bution was the same among patients who were or were
not included.
A total of 204 patients completed the study; 87 (43%)
women and 117 (57%) men. The mean age (50 ± 13
years), time since onset of AS symptoms (24 ± 13 years)
and time since diagnosis (15 ± 11 years) were evenly
distributed between the sexes. Demographic and dis-
ease-related variables are shown in Table 1.
Prevalence of reduced BMD
Among patients under 50 years of age (n = 103), 35
patients (34%) had a BMD Z-score < -1.0 at the hip
and/or AP lumbar spine and 5 patients (4.9%) had BMD
below the expected range for age, that is, a Z-score ≤
-2.0. Among patients 50 years of age or older (n = 101),
44 (43.6%) had osteopenia and 21 (20.8%) had osteo-
porosis using the WHO definition [22]. The lumbar
spine was the most common location for osteoporosis
or BMD below the expected range for age (10%), fol-
lowed by radius (8%) and femoral neck (5%). The preva-
lence of reduced BMD in different locations is shown in
Table 2.
Men had significantly lower BMD at the femoral neck
(mean Z-score -0.215, P = 0.012), compared with the
age- and sex-matched reference values in the DXA-
scanner software. Mean Z-scores were negative at all
measurement sites except the lumbar spine (AP projec-
tion), but was not significantly different to zero. Signifi-
cantly more women aged 50 years or older had
osteoporosis on measurement of AP lumbar spine than
men (12/44, 30% vs. 4/56, 7%, P < 0.001). Consequently,
diagnosis of osteoporosis and osteopenia using the
WHO definition was more prevalent among women
(13/44, 30% and 21/44, 48%, respectively) compared
with men (8/56, 14% and 23/56, 41%, respectively; P =
0.042). BMD below the expected range for age was
equally common in women and men below 50. Men
had a significantly higher mSASSS score (median 8,
range 0 to 72) than women (median 2, range 0 to 46)
(P < 0.001) (Figure 1). Men had significantly higher
aBMD at all measurement sites (P < 0.001 for every
location), but for lumbar vBMD there was no significant
difference between the sexes (P = 0.36). The BASDAI,
BASFI, BASMI and ASDAS were evenly distributed
among women and men.
A total of 36% of women and 8% of men had ever
undergone a DXA examination before the study. Eight
patients were on bisphosphonates at the inclusion. After
the study new treatment with calcium, vitamin D and
bisphosphonates, according to national guidelines, was
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Table 1 Characteristics of 204 patients with ankylosing spondylitis in western Sweden
Patients,
number (%)
Median (range) Mean ± SD
Demographic variables
Sex Women 87 (43)
Men 117 (57)
Age, years NA 49 (17 to 78) 50 ± 13
Postmenopausal women 45/87 (52)
Heredity for fractures 57 (28)
History of vertebral fracture 3 (1)
History of non-vertebral fracture 18 (9)
Current smokers 24 (12)
Ever smoked > 6 months 101 (50)
Daily calcium intake from dairy products NA 600 (0 to 2,640) 668 ± 397
BMI, kg/m2 25 (19 to 46) 26 ± 4
LTPAI total, hours 6 (0 to 42) 7 ± 6
PAHWI total, hours 45 (0 to 160) 40 ± 21
FRAX major osteoporotic fracture (%)
(patients ≥ 40 years)
6.7 (1.2 to 68.0) 9.9 ± 9.7
FRAX hip fracture (%)
(patients ≥ 40 years)
0.8 (0 to 56.0) 2.4 ± 6.0
Disease-related variables
Years since onset of symptoms 24 (2 to 55) 24 ± 13
Years since diagnosis 12 (1 to 47) 15 ± 11
History of anterior uveitis 102 (50)
History of peripheral arthritis 120 (59)
History of coxitis 17 (8)
BASMI, score 3.0 (0.6 to 7.4) 3.1 ± 1.6
BASDAI, score 3.5 (0.0 to 9.6) 3.6 ± 2.1
BASFI, score 2.3 (0.0 to 8.7) 2.7 ± 2.1
BAS-G1, score (last week) 2.9 (0.0 to 10.0) 3.4 ± 2.6
BAS-G2, score (last 6 months) 3.4 (0.0 to 9.7) 3.8 ± 2.6
ASDAS, score 2.3 (0.8 to 5.9) 2.4 ± 0.9
mSASSS, score 5.5 (0.0 to 72.0) 14.2 ± 19.2
Mean ESR, mm/h (2004 to 2008) 16 (2 to 102) 19 ± 15
ESR, mm/h (at inclusion 2009) 11 (2 to 105) 15 ± 14
CRP, mg/L 5 (3 to 80) 9 ± 10
Hemoglobin, g/L 139 (105 to 166) 139 ± 13
WBC, × 109/L 6.7 (2.7 to 18.1) 7.0 ± 2.1
PLT, × 109/L 287 (133 to 506) 299 ± 75
Creatinine, μmol/L 70 (43 to 148) 71 ± 15
HLA-B27 positive 178 (87)
Patients on NSAID 158 (77)
Patients on DMARD 62 (30)
Patients on TNF inhibitor 42 (21)
Patients on GC 7 (3)
GC lifetime use, mg prednisone NA 100 (0, 56390) 1397 ± 5775
Patients on bisphosphonates 8 (4)
Patients on HRT 5 (2)
Patients on calcium and vitamin D 24 (12)
Bone mineral density
aBMD AP lumbar spine, g/cm2 1.02 (0.63 to 1.54) 1.02 ± 0.17
aBMD lateral lumbar spine, g/cm2 0.72 (0.32 to 1.13) 0.73 ± 0.14
vBMD lumbar spine, g/cm3 0.19 (0.09 to 0.27) 0.19 ± 0.03
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initiated in 30 patients (14.2%) and calcium and vitamin D
alone was initiated in 28 patients (13.2%).
Risk factors for reduced BMD
The demographic and disease-related variables explored
for association with BMD are shown in Table 1. Low
BMD correlated significantly with demographic variables
(female sex, older age, low body mass index (BMI), her-
edity for fractures, PAHWI and menopausal status for
women) as well as disease-related variables (long disease
duration, high BASMI, high mSASSS, history of coxitis,
high lifetime use of prednisone, low hemoglobin and ele-
vated inflammatory parameters, high mean ESR, C-reac-
tive protein (CRP), white blood cell count (WBC), platelet
count (PLT) (Table 3). No significant association was
found between BMD and demographic variables (heredity
for osteoporosis, smoking, alcohol intake or LTPAI) or
disease-related variables (anterior uveitis, arthritis, BAS-
DAI, ASDAS, BASFI or BAS-G). The (MHC class 1)
HLAB27-negative patients had significantly lower BMD at
Table 1 Characteristics of 204 patients with ankylosing spondylitis in western Sweden (Continued)
BMD total hip, g/cm2 0.93 (0.54 to 1.42) 0.94 ± 0.14
BMD femoral neck, g/cm2 0.78 (0.48 to 1.20) 0.78 ± 0.13
BMD radius total, g/cm2 0.61 (0.40 to 0.78) 0.61 ± 0.08
BMI, body mass index; LTPAI, Leisure Time Physical Activity Instrument; PAHWI, Physical Activity at Home and Work Instrument; FRAX, World Health Organization
Fracture Risk Assessment Tool (% 10 year probability of major osteoporotic, and vertebral fracture respectively, corresponding to patients aged 40 years or older);
BASMI, Bath Ankylosing Spondylitis Metrology Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional
Index; BAS-G1 and G2, Bath Ankylosing Spondylitis Patient Global Score; ASDAS, ankylosing spondylitis disease activity score; mSASSS, modified Stoke Ankylosing
Spondylitis Spine Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PLT, platelet count; WBC, white blood cell count; NSAID, non-steroidal anti-
inflammatory drug; DMARD, disease modifying anti-rheumatic drug; TNF, tumour necrosis factor; GC, glucocorticoid; HRT, hormone replacement therapy; aBMD,
areal bone mineral density; AP, anteroposterior; vBMD, volumetric BMD

























AP lumbar spine < 50 1.014 ± 0.134 -0.30 ± 1.22 0.02 ± 1.25 2 (5) 0 (0) 41 (95)
≥ 50 0.899 ± 0.150 -1.35 ± 1.37 0.14 ± 1.38 12 (27) 15 (34) 17 (39)
Lat lumbar spine < 50 0.741 ± 0.102 -0.94 ± 1.22 -0.25 ± 1.26 3 (7) 0 (0) 40 (93)
≥ 50 0.616 ± 0.114 -2.43 ± 1.36 -0.05 ± 1.42 20 (45) 15 (34) 9 (20)
Total hip < 50 0.925 ± 0.122 -0.13 ± 1.00 0.07 ± 0.99 0 (0) 0 (0) 43 (100)
≥ 50 0.832 ± 0.108 -0.89 ± 0.88 0.10 ± 0.85 0 (0) 20 (46) 23 (54)
Femoral neck < 50 0.804 ± 0.127 -0.41 ± 1.15 -0.06 ± 1.13 0(0) 0 (0) 43 (100)
≥ 50 0.702 ± 0.103 -1.32 ± 0.93 -0.01 ± 0.91 4 (9) 24 (56) 15 (35)
Total radius < 50 0.576 ± 0.038 -0.05 ± 0.70 0.32 ± 0.74 0(0) 0 (0) 43 (100)
≥ 50 0.517 ± 0.065 -1.14 ± 1.21 0.18 ± 1.09 7 (16) 17 (39) 20 (45)
Men
AP lumbar spine < 50 1.057 ± 0.154 -0.31 ± 1.41 -0.18 ± 1.41 3 (5) 0 (0) 57 (95)
≥ 50 1.092 ± 0.184 0.18 ± 1.67 0.63 ± 1.72 4 (7) 8 (14) 44 (79)
Lat lumbar spine < 50 0.782 ± 0.131 NA NA NA
≥ 50 0.740 ± 0.132 NA NA NA
Total hip < 50 0.999 ± 0.137 -0.23 ± 0.92 -0.05 ± 0.90 1 (2) 0 (0) 59 (98)
≥ 50 0.963 ± 0.136 -0.46 ± 0.90 0.00 ± 0.93 0 (0) 19 (33) 38 (67)
Femoral neck < 50 0.842 ± 0.130 -0.67 ± 0.95 -0.21 ± 0.93 1 (2) 0 (0) 59 (98)
≥ 50 0.773 ± 0.122 -1.16 ± 0.90 -0.21 ± 0.90 5 (9) 25 (44) 27 (47)
Total radius < 50 0.668 ± 0.050 -0.34 ± 0.93 -0.12 ± 0.91 1 (2) 0 (0) 59 (98)
≥ 50 0.633 ± 0.063 -1.03 ± 1.21 -0.25 ± 1.20 9 (16) 18 (33) 28 (51)
Definition of reduced BMD in patients younger than 50 years, BMD below expected range for age (Z-score ≤ -2.0 SD), BMD within expected range for age (Z-
score > -2.0 SD); in patients 50 years or older, World Health Organization definition of osteoporosis: T-score ≤ - 2.5 SD, osteopenia: T-score < -1 to > -2.5 SD;
normal BMD, T-score ≥ -1SD. For lateral lumbar spine BMD in men there are no reference values available for calculation of T- or Z-scores. aData presented as the
sum of patients younger than 50 years, with a Z-score ≤ -2.0 SD and patients 50 years or older with a T-score ≤ -2.5 SD.
AP, anteroposterior; Lat, lateral; BMD, bone mineral density.
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Mean mSASSS score per vertebra 











Figure 1 Mean modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) per vertebra in women and men. C, cervical vertebra; Th,
thoracic vertebra; L, lumbar vertebra; S, sacral vertebra; the upper and lower anterior corners of the vertebrae are denoted by U and L,
respectively.
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the total radius compared with HLAB27-positive patients
(0.564 ± 0.077 vs. 0.612 ± 0.779 g/cm2; P = 0.005), but
there was no difference in BMD at other measurement
sites and no difference in Z-scores for total radial BMD
between HLAB27-negative and -positive patients. The
HLAB27-negative patients were significantly more often
female (P = 0.012).
The variables significantly correlated with BMD were
entered as covariates in stepwise multiple linear regres-
sion analyses with BMD at different measurement sites
as the outcome (Table 4). The most important covari-
ates for low BMD were long disease duration, high
BASMI, low BMI and menopause in women. AP lumbar
spine BMD was mainly associated with demographic
risk factors, whereas lateral lumbar spine BMD and
vBMD were associated to a greater extent with disease-
related risk factors.
A low BMD T-score was defined as a T-score < -1.0
measured with DXA at the lumbar spine (AP projec-
tion), total hip or femoral neck. Logistic regression with











































































































































































n.s. n.s. n.s. n.s.
Results are presented as Spearman’s correlation coefficients and P-values. Coding for categorical variables, 1 = yes, 0 = no; for sex, 1 = woman, 2 = man.
BMI, body mass index; PAHWI, Physical Activity at Home and Work Instrument; BASMI, Bath Ankylosing Spondylitis Metrology Index; mSASSS, modified Stoke
Ankylosing Spondylitis Spine Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WBC, white blood cell count; PLT, platelet count; AP,
anteroposterior; aBMD, areal bone mineral density; vBMD, volumetric BMD; n.s., not significant.
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a forward conditional method was run with low T-score
(yes/no) as the binary outcome and the variables that
were significantly correlated with BMD as covariates.
Significant covariates for low T-score were long time
since onset of AS symptoms (B = 0.036, P = 0.014, odds
ratio 1.727, 95% confidence interval 1.007 to 1.068),
high BASMI (B = 0.301, P = 0.016, odds ratio 1.351,
95% confidence interval 1.057 to 1.068), low BMI (B =
-0.162, P < 0.001, odds ratio 0.850, 95% confidence
interval 0.781 to 0.925) and for women menopausal sta-
tus (B = 0.869, P = 0.040, odds ratio 2.384, 95% confi-
dence interval 1.041 to 5.461).
Comparison of anteroposterior DXA and lateral DXA
Significantly more women had a lumbar spine BMD T-
score ≤ -2.5 (age ≥ 50) or Z-score ≤ -2.0 (age < 50) when
measured by lateral DXA (n = 23, 26%) compared with AP
DXA (n = 14, 16%; P = < 0.001) (Table 2). T- and Z-scores
for lateral spine DXA were not available for the men.
Lumbar spine BMD was significantly higher measured
in the AP compared with the lateral projection (P <
0.001) (Table 1). The difference (AP minus lateral pro-
jection DXA BMD) increased with increasing mSASSS
(rS = 0.389, P < 0.001), BASMI (rS = 0.296, P = 0.001),
age (rS = 0.309, P = 0.001) and disease duration (rS =
0.268, P = 0.004) in men, but not in women.
Since men had significantly higher mSASSS than
women the male subgroup was chosen to further study
the effects of increasing ankylosis on BMD. Increasing
mSASSS in men was significantly correlated with lower
lumbar spine vBMD (rS = -0.389, P < 0.001), lower lat-
eral spine BMD (rS = -0.191, P = 0.041), femoral neck
BMD (rS = -0.324, P < 0.001) total hip BMD (rS =
-0.201, P = 0.030) and total radial BMD (rS = -0.269, P
= 0.004), but not with AP lumbar spine BMD (rS =
0.152, P = 0.103) (Figure 2). Higher BASMI in men also
correlated significantly with lower BMD at all measure-
ment sites, except for AP lumbar spine BMD, which
tended to be higher, but was not significantly so.
Discussion
The present study demonstrates that osteoporosis is
common in Swedish patients with AS, but is often
undiagnosed and thus untreated. BMD was below the
expected range for age in 5% of patients under the age of
50 years. Osteoporosis, as defined by the WHO, was
diagnosed in 21% of patients aged 50 years or older (in
30% of the women and 14% of the men). Most patients
with osteoporosis were undiagnosed before the study.
The prevalence of osteoporosis found in the present
study is comparable with the prevalence in the Swedish
general population aged 50 to 80 years, where 21.2% of
women and 6.3% of men have been identified as having
osteoporosis [25]. The results indicate that the increased
risk of osteoporosis in AS compared with the general
population is especially accentuated in male patients,















0.829 0.539 0.2390 0.783 0.654 0.625
R2 all variables 0.290 0.245 0.266 0.402 0.343 0.591
R2 for demographic variables 0.254 0.163 0.171 0.338 0.279 0.569
R2 for disease related variables 0.079 0.181 0.276 0.174 0.198 0.253
Demographic variables B P-value B P-value B P-value B P-value B P-value B P-value
Sex NA NA NA -0.056 0.009 NA -0.082 < 0.001
Age, years NA NA NA NA NA -0.001 0.002
Menopause -0.156 < 0.001 -0.104 < 0.001 NA -0.053 0.048 -0.076 < 0.001 -0.035 0.009
BMI, kg/m2 0.014 < 0.001 NA NA 0.014 < 0.001 0.011 < 0.001 0.004 < 0.001
Disease-related variables B P -value B P -value B P -value B P -value B P -value B P -value
Years since diagnosis NA -0.003 < 0.001 NA NA NA NA
Years since symptom debut NA NA -0.001 < 0.001 -0.002 0.019 -0.002 0.028 NA
BASMI NA NA -0.006 < 0.001 -0.023 < 0.001 -0.029 < 0.001 -0.008 0.016
Hemoglobin NA 0.002 0.008 NA NA NA NA
WBC NA NA NA -0.007 0.05 NA NA
PLT 0.000 0.003 NA NA NA NA NA
All demographic and disease-related variables that were significantly correlated with BMD in the first analyses were entered as covariates. The table shows only
covariates that remained significantly associated with BMD in the stepwise multiple linear regression models. Coding for categorical variables, 1 = yes, 0 = no; for
sex, 1 = woman, 2 = man. Beta values are unstandardized regression coefficients.
AP, anteroposterior; BASMI, Bath Ankylosing Spondylitis Metrology Index; aBMD, areal bone mineral density; vBMD, volumetric BMD; BMI, body mass index;
mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; PLT, platelet count; WBC, white blood cell count.
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which is in accordance with findings in another study
[26].
In the current study osteoporosis and osteopenia in
the lumbar spine were more common in women than in
men in the age-group of 50 years or older when mea-
sured with AP lumbar DXA, and thus more women
were diagnosed as osteoporotic. The prevalence of
osteoporosis and osteopenia was equal among women
and men at all other locations. The high prevalence of
syndesmophytes in the men may have resulted in falsely
elevated BMD causing an underestimation of male
osteoporosis at the lumbar spine.
The results from the present study indicate that osteo-
porosis and osteopenia affect both the central and the per-
ipheral skeleton. We found almost as many patients with
BMD below the expected range for age or osteoporosis at
the radius (n = 17, 8%) as in the lumbar spine (n = 24,
12%). Results from earlier studies indicate that osteoporo-
sis in AS is predominantly confined to the central skeleton
[27,28]. In one study no correlation was found between
bone density at the forearm measured with peripheral
quantitative computed tomography (pQCT) and DXA and
quantitative CT (QCT) measurements of BMD at the lum-
bar spine or hip [29]. Quantitative ultrasound studies of
the heel in patients with AS have inconsistent findings,
with normal results in one study, and signs of peripheral
osteoporosis in another [30,31]. The theory that osteo-
porosis is a general process affecting the whole skeleton in
AS was supported by a study of bone biopsies from the
iliac crest, showing trabecular thinning and low trabecular
peripheral bone volume strongly correlated with lumbar
spine BMD measured using QCT [32].
There is uncertainty about how to treat osteoporosis































































rS= 0.152   p=0.103 rS= -0.191   p=0.042 
rS= -0.389   p<0.001 rS= -0.324   p<0.001 
Figure 2 Scatter plots of modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and BMD measured at different locations.
Spearman’s correlation coefficients (rS) and P-values for the correlations are given.
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in respect to their effect on disease activity in AS, but
their effects on fractures, BMD and the new bone for-
mation in AS needs to be further investigated. Pamidro-
nate has been reported to hamper disease activity in AS
[33,34]. In a recent placebo-controlled study of alendro-
nate 70 mg weekly, no improvement of AS symptoms or
disease activity was found [35].
In the current study we found that low BMD was
associated with older age, longstanding disease, syndes-
mophyte formation, impaired back mobility, history of
coxitis, use of glucocorticoids and laboratory signs of
inflammation. Menopause was a strong risk factor for
women. No connection was found between low BMD
and the disease indices BASDAI, BASFI, BAS-G or
ASDAS. BASMI and ASDAS were associated with
inflammatory parameters (ESR, CRP), but BASDAI,
BASFI and BAS-G were not.
The association between extensive syndesmophyte for-
mation, restriction of spinal movement and osteoporosis
has been demonstrated previously [26,29,36]. One study
found significant correlation between low lumbar spine
BMD and elevated ESR and CRP [37]. Two follow-up
studies have shown that patients with AS and persistent
inflammation, that is, with elevated ESR or CRP, devel-
oped significant decreases in BMD, whereas patients
with low inflammatory activity did not [38,39].
In men, who had significantly higher mSASSS than
women, increasing mSASSS and BASMI were signifi-
cantly associated with decreasing vBMD and lateral
BMD at the lumbar spine, along with lower BMD at the
hip and radius, while AP lumbar BMD had a non-signif-
icant tendency to increase. Our interpretation of the
results is that in comparison with AP spine BMD, lum-
bar spine vBMD and lateral lumbar spine BMD are less
affected by the new bone formation in AS and hence
are more adequate tools in assessing osteoporosis and
osteopenia, especially in male patients in AS.
Lateral lumbar spine BMD is usually lower than AP
BMD, because the lateral DXA scan measures only the
trabecular-rich vertebral body, whereas the AP scan
includes both the vertebral body and the posterior part
of the vertebra, mainly consisting of dense cortical bone.
AP scanning is also affected by artefacts due to to osteo-
phytes, aortic calcifications and degenerative changes in
the facet joints of elderly people and from hyperostosis
in AS. The trabecular bone is more metabolically active
than the cortical bone, therefore a decrease in BMD is
first found in the trabecular bone. Consequently lateral
lumbar spine BMD declines faster than AP BMD in
early osteoporosis [40,41].
The current study demonstrates that lateral lumbar
spine DXA is more sensitive than AP DXA in detecting
osteoporosis and osteopenia in AS. The same results
have been reported in two studies using lateral DXA of
vertebra L3 in patients with AS [42,43]. Other studies
have shown that lateral DXA is more sensitive than AP
DXA in detecting osteopenia and osteoporosis in degen-
erative spinal disease [44]. In one study of 100 AS
patients and 58 healthy controls assessed with both AP
and lateral lumbar DXA using a scanner similar to the
one used in the current study, the authors reported that
lumbar spine BMD was significantly lower in AS
patients compared with healthy controls when measured
by lateral projection DXA, but not when measured by
AP DXA [45]. However, to apply lateral DXA in clinical
practice, reference intervals based on measurements on
large populations of healthy men and women are
required. Most likely, new threshold values for definition
of osteoporosis have to be defined to avoid overestima-
tion of osteoporosis with lateral DXA. The current
WHO definition of osteoporosis is based on the PA pro-
jection and according to the Official Positions of the
International Society for Clinical Densitometry 2007, the
lateral spine should not be used for diagnosis of osteo-
porosis, but it may have a role in monitoring [23].
Conclusions
Osteoporosis and osteopenia are common in Swedish
patients with AS and affected half of our study popula-
tion. Low BMD was found in both the central and the
peripheral skeleton. Osteoporosis was often undiagnosed
and untreated, particularly in male patients with AS.
Older age and high disease burden, that is, long disease
duration, impaired back mobility, syndesmophyte forma-
tion and elevated inflammatory parameters, indicated
increased risk of osteoporosis. Lateral and vBMD at the
lumbar spine were less affected by progressive ankylosis
in AS compared with AP BMD. In addition, lateral DXA
was more sensitive in detecting osteoporosis and osteo-
penia than AP DXA. We suggest that lateral lumbar
spine DXA with calculation of vBMD may become valu-
able tools in the diagnosis and follow-up of osteoporosis
in AS, but validation of the methods in larger reference
populations is needed.
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